Advisors Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Advisors Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-100	Closed	-$2K	–	1583
2020 Q1	$2K	Sell	100 -298	-75%	-$6.26K	﹤0.01%	1466
2019 Q4	$9K	Sell	398 -285	-42%	-$6.92K	﹤0.01%	1500
2019 Q3	$19K	Sell	683 -265	-28%	-$7.85K	﹤0.01%	1482
2019 Q2	$31K	Sell	948 -75	-7%	-$2.57K	﹤0.01%	1435
2019 Q1	$36K	Buy	1,023 +236	+30%	+$8.78K	﹤0.01%	1655
2018 Q4	$26K	Buy	787 +162	+26%	+$6.97K	﹤0.01%	1491
2018 Q3	$31K	Buy	625 +366	+141%	+$18.1K	﹤0.01%	1481
2018 Q2	$16K	Buy	259 +207	+398%	+$10.7K	﹤0.01%	1517
2018 Q1	$2K	Buy	+52	New	+$2.17K	﹤0.01%	1511

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Advisors Asset Management's SUPN Position: Q2 2020 in Review

Advisors Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2020, closing a stake of 100 shares — an estimated $2K sold.

Advisors Asset Management first reported a position in SUPN in Q1 2018 and held it in 9 quarters. The position peaked at $36K in Q1 2019. 218 funds tracked by Wall St. Rank hold SUPN as of Q2 2020.

Advisors Asset Management reported no remaining Supernus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Advisors Asset Management sold 100 Supernus Pharmaceuticals shares in Q2 2020, an estimated $2K.
Advisors Asset Management first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 9 quarters.
Advisors Asset Management's Supernus Pharmaceuticals position peaked at $36K in Q1 2019.
218 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2020.

Based on Advisors Asset Management's 13F filing for Q2 2020, filed 12 Aug 2020.